Background: The BRAFV600E mutation is the most common genetic alteration in papillary thyroid carcinomas (PTCs). Transgenic mice overexpressing BRAFV600E in their thyroids under control of the thyroglobulin promoter (Tg-BRAF2 mice) developed invasive PTCs with high penetrance. However, these mice showed elevated thyrotropin (TSH) levels, which also stimulate the proliferation of thyrocytes and tumorigenesis. The purpose of the present study was to investigate how TSH signaling cooperates with BRAFV600E in the process of thyroid carcinogenesis. Methods: We crossed Tg-BRAF2 mice with TSH receptor knockout (TshR-/-) mice. Four genetically distinct mice groups - Brafwt/TshR+/- (group 1), Brafwt/TshR-/- (group 2), Tg-BRAF2/TshR+/- (group 3), and...
Papillary thyroid cancer (PTC) is the most common endocrine malignancy, accounting for 85–90% of all...
Papillary thyroid carcinoma (PTC) is the most frequent histological subtype of thyroid cancers (TC),...
Background: While the development of new treatments for aggressive thyroid cancer has advanced in th...
Background: The BRAFV600E mutation is the most common genetic alteration in papillary thyroid carcin...
The mutant BRAF (BRAFV600E) is the most common genetic alteration in papillary thyroid carcinomas (P...
The BRAFV600E mutation is the most prevalent driver mutation of sporadic papillary thyroid cancers (...
Papillary thyroid carcinoma (PTC) is the most frequent histological subtype of thyroid cancers (TC),...
Cancer cells hijack developmental growth mechanisms but whether tissue morphogenesis and architectur...
UNLABELLED Thyroid malignancies are the most common type of endocrine tumors. Of the various hist...
Thyroid malignancies are the most common type of endocrine tumors. Of the various histologic subtype...
AbstractB-RafV600E oncogene mutation occurs most commonly in papillary thyroid carcinoma (PTC) and i...
Purpose Down-regulation of thyroid hormone receptor beta (THRβ) gene has been described in several ...
Papillary thyroid cancer (PTC) is the most common endocrine malignancy, accounting for 85–90% of all...
Background: Constitutively active thyrotropin receptor (TSHR) mutations are the most common etiology...
Cancer cells hijack developmental growth mechanisms but whether tissue morphogenesis and architectur...
Papillary thyroid cancer (PTC) is the most common endocrine malignancy, accounting for 85–90% of all...
Papillary thyroid carcinoma (PTC) is the most frequent histological subtype of thyroid cancers (TC),...
Background: While the development of new treatments for aggressive thyroid cancer has advanced in th...
Background: The BRAFV600E mutation is the most common genetic alteration in papillary thyroid carcin...
The mutant BRAF (BRAFV600E) is the most common genetic alteration in papillary thyroid carcinomas (P...
The BRAFV600E mutation is the most prevalent driver mutation of sporadic papillary thyroid cancers (...
Papillary thyroid carcinoma (PTC) is the most frequent histological subtype of thyroid cancers (TC),...
Cancer cells hijack developmental growth mechanisms but whether tissue morphogenesis and architectur...
UNLABELLED Thyroid malignancies are the most common type of endocrine tumors. Of the various hist...
Thyroid malignancies are the most common type of endocrine tumors. Of the various histologic subtype...
AbstractB-RafV600E oncogene mutation occurs most commonly in papillary thyroid carcinoma (PTC) and i...
Purpose Down-regulation of thyroid hormone receptor beta (THRβ) gene has been described in several ...
Papillary thyroid cancer (PTC) is the most common endocrine malignancy, accounting for 85–90% of all...
Background: Constitutively active thyrotropin receptor (TSHR) mutations are the most common etiology...
Cancer cells hijack developmental growth mechanisms but whether tissue morphogenesis and architectur...
Papillary thyroid cancer (PTC) is the most common endocrine malignancy, accounting for 85–90% of all...
Papillary thyroid carcinoma (PTC) is the most frequent histological subtype of thyroid cancers (TC),...
Background: While the development of new treatments for aggressive thyroid cancer has advanced in th...